malignancies, but long-term disease control occurs in only approximately 50% of patients with B-63 ALL 1 and large B cell lymphoma 2 , and is even less frequent in CLL 3 . Moreover, despite numerous 64 trials, CAR T cells have not mediated sustained antitumor effects in solid tumors 4 . Numerous 65 factors limit the efficacy of CAR T cells, including heterogeneous antigen expression and a 66 requirement for high antigen density for optimal CAR function enabling rapid selection of antigen 67 loss variants 5-7 , the suppressive tumor microenvironment 8 and intrinsic T cell dysfunction as a 68 result of T cell exhaustion 3, 9, 10 . T cell exhaustion has been increasingly incriminated as a cause of 69
T cell dysfunction in CAR T cells. Tonic antigen-independent signaling, due to scFv aggregation, 70
commonly occurs in T cells expressing CARs and can induce rapid exhaustion 9 . Integration of the 71 CD28 endodomain into second generation CAR T cell receptors enhances expansion, but also 72 predisposes CAR T cells to exhaustion, both in the setting of tonically signaling receptors and in 73 CD19-28z CAR T cells exposed to high tumor burdens 9 . Increased frequency of T cells bearing 74 exhaustion characteristics contained within CD19-BBz CAR grafts were recently demonstrated to 75 distinguish non-responding from responding patients treated for CLL 3 . Recent studies have also 76 suggested that engineering CAR T cells to be less susceptible to exhaustion can enhance 77 antitumor effects, as reported following integration of the CD19-28z CAR into the TRAC locus, 78
which apparently tuned the activating signal and thus prevented exhaustion 10 , and as suggested 79
in a recent case report, whereby apparent cure via one clonal CD19-CAR T cell was associated 80
with insertional mutagenesis mediated disruption of TET2 11 . Together, a broad base of data from 81 diverse studies implicates intrinsic T cell dysfunction due to T cell exhaustion as a major factor 82 limiting the efficacy of CAR T cell therapeutics and raises the prospect that engineering 83 exhaustion-resistant CAR T cells could substantially improve clinical outcomes. 84 T cell exhaustion is characterized by overexpression of cell surface receptors that mediate 85 inhibitory signals and widespread transcriptional and epigenetic alterations [12] [13] [14] [15] [16] , although a 86 comprehensive understanding of the mechanisms responsible for impaired function in exhausted 87
T cells is lacking. PD-1 blockade can reinvigorate some exhausted T cells 17 , but is unable to fully 88 restore function, and trials using PD-1 blockade to prevent or reverse exhaustion in CAR T cells 89 have not yet demonstrated efficacy 18 . Using a model wherein healthy T cells are driven to 90 exhaustion via expression of a tonically signaling CAR, we observed that exhausted human T cells 91 rapidly developed a profound defect in IL-2 production. This phenotype was associated with 92 widespread epigenomic dysregulation of AP-1 transcription factor binding motifs and 93 overexpression of numerous bZIP and IRF family transcription factors that have been implicated 94 in inhibitory AP-1 signaling. Therefore, we tested the hypothesis that dysfunction in this setting 95 resulted from an imbalance between activating and inhibitory bZIP/IRF transcriptional activity, 96 which could be rectified by enforced expression of c-Jun, an AP-1 family transcription factor 97 associated with productive T cell activation. Consistent with this hypothesis, c-Jun overexpression 98 rendered CAR T cells exhaustion-resistant, as demonstrated by enhanced expansion potential in 99 vitro and in vivo, increased functional capacity, diminished terminal differentiation and improved 100 antitumor potency in numerous models. 101 102 RESULTS 103
Expression of the HA-28z CAR in human T cells rapidly induces hallmark features of T cell 104 exhaustion 105 . c) CD19-28z primarily comprise T stem cell memory (CD45RA + CD62L + ) and central memory (CD45RA -CD62L + , whereas HA-28z primarily comprise CD45RA -CD62Leffector memory cells (D10). d) IL-2 (left) and IFNg (right) release following 24-hour co-culture with CD19 + GD2 + Nalm6-GD2 leukemia cells. Error bars represent mean ± SD from triplicate wells. One representative donor shown for each assay. e) Principle component analysis (PCA) of global transcriptional profiles of Naïve-and CM-derived CD19 or HA CAR T cells at days 7, 10, and 14 in culture. PC1 (39.3% variance) separates CD19 from HA CAR T cells. f) Gene expression of the top 200 genes driving PC1. Genes of interest in each cluster are listed above. g) Differentially accessible chromatin regions in CD8 + CD19 and HA-28z CAR T cells (D10). Both N and CM subsets are incorporated for each CAR. h) PCA of ATAC-seq chromatin accessibility in CD19 or HA-28z CAR T cells (D10). PC1 (76.9% variance) separates CD19 from HA CAR samples. i) Global chromatin accessibility profile of subset-derived CD19 and HA-28z CAR T cells (D10). Top 5000 differentially accessible regions (peaks). j) Differentially accessible enhancer regions in CD19 and HA CAR T cells in the CTLA4 (top) or IL7R (bottom) loci. N -naïve, CMcentral memory. * p < .05, ** p < .01, *** p < .001. ns p >.05. formation ( Fig. 1c , Extended Data Fig. 1e ), and diminished IFN-g and markedly decreased IL-2 116 production when stimulated with CD19 + GD2 + Nalm6 leukemia ( Fig. 1d ). 117
To better elucidate the molecular underpinnings of T cell exhaustion in this system, we 118 interrogated the transcriptome of HA-28z compared to CD19-28z CAR T cells. We transduced 119 purified naïve (N) and central memory (CM) T cells with HA or CD19-28z CAR then isolated RNA 120 on days 7, 10, and 14 of culture. Sorting pre-selected subsets allowed us to assess the impact of 121 T cell differentiation state and the distinction between CD4 and CD8 exhaustion in the 122 development of T cell exhaustion in this model. Principle component analysis (PCA) across all 24 123 samples revealed that the strongest driver of variance was the presence of the HA-vs CD19-28z 124 CAR (PC1, 39.3% variance, Fig. 1e ), consistent with a model wherein tonic signaling in HA-28z CAR 125
T cells drives exhaustion in all T cell subsets studied. Distinctions were, however, observed based 126 upon the starting differentiation state, since N vs CM was reflected in PC2 (22.88% variance) 127
(Extended Data Fig1f) and between CD4 vs CD8 populations, which drove PC3 (11.9% variance) 128 ( Fig. 1e and Extended Data Fig. 1f ). 129
Among the top 200 genes driving PC1 (most differentially expressed in HA-vs CD19-28z 130 CAR T cells across all subsets) ( Fig. 1f ) were genes associated with activation (IFNG, GZMB, IL2RA), 131 inhibitory receptors (LAG3, CTLA4) and some inflammatory chemokines/cytokines (CXCL8, IL13, 132 IL1A), whereas genes downregulated in HA-28z CAR T cells include genes associated with naïve 133 and memory T cells (IL7R, TCF7, LEF1, and KLF2). Using GSEA we demonstrated that genes 134 upregulated in day 10 HA-28z vs CD19-28z CAR T cells overlap with exhaustion-associated gene 135 sets previously described in chronic LCMV mouse models 13 (Extended Data Fig. 1g ). Although the 136 degree of exhaustion in GD2-28z CAR T cells is less profound, differential gene expression analysis 137 of single cell GD2-28z vs CD19-28z CAR T cells revealed a similar gene expression profile 138 (Extended Data Fig. 2 ). Together, these data credential HA-28z and GD2-28z expressing T cells as 139 models for the study of human T cell exhaustion. 140
T cell exhaustion is associated with changes in chromatin accessibility in mouse models 141 and human patients with chronic viral infections and cancer 12,17 . Chromatin accessibility analyses 142 using ATAC-seq 20 (Extended Data Fig. 3 ) of N or CM derived CD4 + and CD8 + HA-28z vs CD19-28z 143 CAR T cells demonstrated significant changes in the epigenetic signature on day 10 of culture (Fig.  144 1g) with CD8 + HA-28z CAR T cells displaying >20,000 unique chromatin accessible regions (peaks) 145 compared to < 3,000 unique peaks in CD8 + CD19-28z CAR T cells (FDR < 0.1 and log2FC > 1). These 146 patterns of changes in exhaustion-induced chromatin accessibility were similar in CD4 + T cells 147
(Extended Data Fig. 4a ). Similar to the transcriptomic analysis, PCA revealed HA-vs. CD19-CAR as 148 the strongest driver of differential chromatin states (PC1 variance 79.6%, Fig. 1h ), with weaker 149 but significant differences observed between N vs CM cells (PC2 variance 7.4%), and between the 150 CD4 vs CD8 subsets (PC3 variance 6.5%)(Extended Data Fig. 4b ). Clustering the top 5000 151 differentially accessible regions (peaks) revealed globally similar chromatin accessibility in HA-152 28z CAR T cells regardless of starting subset ( Fig. 1i ). As expected, HA-28z CAR T cells 153 demonstrated increased chromatin accessibility in regulatory sites near exhaustion-associated 154 genes such as CTLA4, and decreased accessibility in regulatory sites near memory associated 155 genes such as IL7R (Fig. 1j ). 156 157
Epigenetic and transcriptional analyses reveal a strong AP-1 signature in exhausted CAR T 158 cells 159
To identify transcriptional programs predicted to be dysregulated by the epigenetic 160 changes induced in exhausted T cells, we compared transcription factor (TF) motif deviation in 161 exhausted vs healthy CAR T cell open chromatin. Using ChromVAR analysis 21 , we identified the 162 25 most differential motifs across all 8 samples and found that many of these belong to the AP-163 1(bZIP) family ( Fig. 2a ). Similarly, TF motif enrichment analysis revealed AP-1/bZIP and bZIP/IRF 164 binding motifs as among the most significantly enriched in exhausted CAR T cells ( Fig. 2b and  165 Extended Data Fig. 4c ). 166
167
Clustering differentially accessible peaks by shared TF motif enrichment identified 4 168 clusters associated with exhausted HA-28z CAR T cells (Extended Data Fig. 4d , EX1-EX4). 169 Exhaustion-associated clusters contained peaks in the vicinity of genes like BTLA, CD39, IFNG, 170 and CTLA4, suggesting common TF regulation of exhaustion-associated genes. All 4 exhaustion-171 associated clusters displayed strong enrichment for AP-1 and AP-1-related family TFs, 172
implicating widespread AP-1 TF modulation of exhaustion-associated gene regulation. We also 173 observed strong enrichment for NFkB, NFAT, and RUNX TF family motifs in some of the 174 exhaustion clusters, indicating that a subset of exhaustion-related genes may be regulated by 175 these transcriptional programs and reproduce epigenetic signatures of exhaustion observed in 176 other models 12, 17, 22 . Interestingly, the clusters associated with healthy CD19-28z CAR T cells 177 (HLT1-2) showed a similar profile to a cluster strongly associated with Naïve starting subset. 178
This observation is consistent with the idea that healthy CAR T cells maintain an epigenetic 179 signature more closely resembling naïve-derived T cells, a subset associated with increased 180 persistence and efficacy in adoptive T cell therapy 23 , whereas chronic antigen stimulation 181 results in broad divergent epigenetic reprogramming. were among the most differentially expressed and broadly connected in exhausted GD2-28z 203 CAR T cell networks ( Fig. 2e and Extended Data Fig. 2 ).
205 c-Jun overexpression (OE) reduces functional exhaustion in CAR T cells 206
Based upon the evidence that exhausted CAR T cells manifest very poor IL-2 production 207 ( Fig. 1d ) and preferentially overexpress bZIP and IRF transcription factors that drive 208 immunoregulatory and exhaustion-associated programs, we hypothesized that T cell dysfunction 209
in exhausted cells might be due to a relative deficiency in c-Jun/c-Fos heterodimers necessary to 210 drive IL-2 transcription. To test this, we co-transduced HA-28z and CD19-28z CAR T cells with a 211 bicistronic lentiviral vector to overexpress c-Jun and c-Fos. HA-28z CAR T cells engineered to 212 overexpress AP-1 demonstrated increased IL-2 production upon antigen stimulation (Extended 213 T cells demonstrated a remarkable increase in IL-2 and IFNg production compared to control HA-227 28z CAR T cells ( Fig. 3d-e ). The fold increase in cytokine production in the setting of c-Jun OE was 228 substantially greater for JUN-HA CAR compared to JUN-CD19 CAR T cells (Extended Data Fig 7a-229 b). Similarly, JUN-HA CAR T cells demonstrated increased frequencies of SCM/CM vs E/EM 230 subsets compared to HA-28z CAR T cells ( Fig. 3f ), whereas no significant difference in subset 231 composition was observed between CD19 and JUN-CD19 CAR T cells at day 10 of culture. 232
Together, the data are consistent with a model wherein c-Jun OE is functionally more significant 233 in exhausted T cells, which overexpress inhibitory bZIP and IRF TFs. 234
To assess whether c-Jun OE enhances long-term proliferative capacity, which is associated 235 with antitumor effects in solid tumors 31 , and to test whether c-Jun OE could augment function in 236 CAR T cells without tonic signaling (CD19-28z, CD19-BBz) or in those with lesser levels of tonic 237 signaling (GD2-BBz), we measured in vitro expansion of JUN-CAR T cells from 3 different healthy 238 donors over a protracted period (Extended Data Fig. 7c ). We observed a consistent pattern of 239 enhanced long-term proliferative capacity in the presence of c-Jun OE, which remained IL-2-240 dependent, as these cells immediately ceased expansion in the absence of IL-2 ( Fig. 3g ). (1/2max at 6.76 hours following drug exposure), whereas JUN-DD rapidly became undetectable 266 in the absence of TMP (t1/2 of 1.84 hours) (Fig 4d and Extended Data Fig. 8a-b tumor-free survival (Fig. 5a-c) . We next sought to address whether c-Jun OE could enhance the 326 functionality of CARs targeting solid tumors. We evaluated the effect of JUN-CAR using Her2 and 327 GD2 targeting CARs incorporating the 4-1BB costimulatory domain, which has become the 328 preferred signaling domain for imparting long-term persistence [35] [36] [37] . In a protracted ex vivo killing 329 assay of 143b osteosarcoma JUN-Her2-BBz CAR T cells manifested significantly more potent 330 killing activity at a 1:8 effector:target (E:T) ratio, consistent with enhanced potency on a per cell 331 basis ( Fig. 5d-e ). Similarly, JUN-Her2-BBz CAR T cells prevented tumor growth in vivo and led to 332 dramatically improved long-term survival, which was associated with increased T cell expansion 333
in vivo (Fig. 5f-h) . Similar results were observed when comparing GD2-BBz and JUN-GD2-BBz CAR 334
T cells against 143b osteosarcoma (Extended Data Fig. 9 ), confirming the benefit of c-Jun OE in 335 CAR T cells responding to solid tumors and in CAR T cells incorporating 4-1BB signaling domains. 336
338 c-Jun overexpression decreases CAR T cell activation threshold and permits recognition of 339 tumor cells with lower antigen density. 340
The elevated levels of inhibitory AP1 family members in exhausted CAR T cells raised the 341 prospect that dysfunction in exhausted CAR T cells relates, at least in part, to a higher threshold 342
for activation, which might be normalized by restoring the balance of activating vs inhibitory AP1 343 family members. To test this, we compared cytokine production of HA-CAR vs. JUN-HA-CAR T 344 cells in response to serial dilutions of plate-bound 1A7, an anti-idiotype antibody that binds the 345 14g2a scFv, allowing for control of stimulus strength. c-Jun OE substantially enhanced maximal 346 IL-2 and IFNg produced, and also substantially lowered the amount of 1A7 needed to induce IL-2 347 secretion, consistent with a reduced activation threshold in JUN-HA-CAR T cells ( Fig. 6a-b ). 348
Limiting target antigen expression levels on tumor cells is increasingly recognized to 349 limit CAR functionality 5,6,38 . We recently reported CD22 dim relapses in leukemia patients 350
following initial responses to CD22 CAR therapy. Because c-Jun OE lowers the activation 351 threshold in tonically signaling HA-28z CAR T cells, we assessed whether JUN-CARs would 352 recognize and kill tumor cells with lower antigen density, which may escape recognition by 353 control CAR T cells. When JUN-CD22-BBz CAR (Fig. 6c ) T cells were challenged with CD22 low 354 leukemia ( Fig. 6d ), JUN-CAR T cells exhibited increased cytokine production in vitro (Fig. 6e ) and 355 dramatically increased in vivo anti-tumor activity ( Fig. 6f-i 
DISCUSSION

369
Several lines of evidence implicate exhaustion in limiting the potency of CAR T cells 3,9-11 . 370
Using a tonically signaling CAR capable of inducing the hallmark features of exhaustion during a 371 controlled in vitro culture system, we comprehensively profiled the transcriptomic and 372 epigenetic state of human CAR T cell exhaustion. Our findings largely align with data generated 373 from mice and humans with cancer and chronic viral infection, implying that CAR T cell exhaustion 374
is similar to T cell exhaustion occurring in other settings and thus validate the model system as 375
relevant for the study of human T cell exhaustion. Our ATAC-seq data identified novel 376 exhaustion-specific regulatory regions, which allowed us to identify transcriptional regulators, 377 most notably of the AP-1 related bZIP/IRF families, likely responsible for driving exhaustion-378 associated gene expression. 379
Given the combined observations of a profound defect in IL-2 production, significant Furthermore, the finding that the c-Jun AA JNP-mutant, which should limit the transactivation 401 potential of c-Jun, also mediated exhaustion-resistance, suggests that c-Jun overexpression may 402 rescue function by an alternative mechanism. A second model posits that c-Jun OE acts in a 403 dominant negative fashion by indirectly antagonizing IRF/BATF or other inhibitory homo-or 404 heterodimers which mediate transcriptional activity that contributes to the exhaustion profile, 405
as previously reported 14 . The inability for Fos overexpression to enhance function is consistent 406
with the indirect antagonization model, as Fos has not been described to heterodimerize with 407 BATF proteins. Further, the previously reported finding that BACH2 protects from terminal 408 effector differentiation by blocking AP-1 sites 40 is also consistent with an indirect model wherein 409
c-Jun similarly acts to block access of inhibitory AP-1 complexes to enhancer regions, as terminal 410 effector differentiation is a hallmark of exhaustion in our model. Whether through a direct or 411 indirect mechanism, our data are consistent with the hypothesis that an imbalance of c-Jun to 412 other bZIP/IRF TFs contributes to the biology of human T cell exhaustion, and that functional 413 rescue can be achieved by c-Jun replacement. 414
The impressive effects of c-Jun overexpression in numerous preclinical tumor models 415 raise the prospect of clinical testing of JUN-CAR T cells. c-Jun was first discovered as the cellular 416 homolog (c-Jun) of v-Jun 41 , the viral oncogene from avian sarcoma virus and c-Jun expression has 417 been described in cancer. However, despite extensive study, tumor promoting effects of c-Jun in 418 human cancer are limited to JUN amplification in undifferentiated soft-tissue sarcomas, where it 419 appears to prevent adipocyte differentiation 42 , and overexpression of c-Jun in Hodgkin's Disease 420
and anaplastic large cell lymphoma, where it may enhance proliferation and suppress 421 apoptosis 43 . c-Jun has not been implicated as an oncogene in mature T cells, which appear to be 422 generally resistant to transformation. Consistent with this finding, we observed that c-Jun 423 overexpressing T cells manifest increased proliferative capacity in vitro and in vivo, but remain IL-424 2-dependent and we observed no evidence for leukemic transformation. Ras-mediated 425 transformation in rodent models required JNP 44 , therefore, our c-Jun AA mutant, which equally 426 rescues CAR T cell function, could be implemented to mitigate theoretical oncogenic risk. 427
Furthermore, we developed a regulatable version of c-Jun that can be induced using 428 trimethoprim, an FDA approved small molecule. The favorable kinetics for rapid, inducible 429 stabilization of c-Jun could allow fine-tuned control of c-Jun expression in CAR T cells in patients 430
while mitigating long-term risk. An alternative approach to address the theoretical risks of JUN 431 overexpression would be to integrate a suicide domain into JUN-CAR T cells, an approach that 432 has already been tested in clinical trials 45 . 433
In summary, our findings highlight the power of a deconstructed model of human T cell 434 exhaustion to interrogate the biology of this complex phenomena. Using this approach, we 435 discovered a fundamental role for the AP-1/bZIP family in human T cell exhaustion and 436 demonstrated that c-Jun OE renders CAR T cells exhaustion-resistant, which enhances their 437 capacity to control tumor growth in vivo, and enhances recognition of antigen-dim targets, thus 438
addressing major barriers to progress with this novel class of therapeutics. 439 440
METHODS 441
Viral vector construction 442 MSGV retroviral vectors encoding the following CARs were previously described: CD19-28z, 443
CD19-BBz, GD2-28z, GD2-BBz, Her2-BBz, and CD22-BBz. To create the HA-28z CAR, a point 444 mutation was introduced into the 14G2a scFv of the GD2-28z CAR plasmid to create the E101K 445 mutation. The "4/2NQ" mutations 46 were introduced into the CH2CH3 domains of the IgG1 446 spacer region to diminish Fc receptor recognition for in vivo use of HA-28z CAR T cells. cases, GFP cDNA was also subcloned upstream of the CAR to create GFP-P2A-CAR vector 455 controls. 456
Viral vector production 457
Retroviral supernatant was produced in the 293GP packaging cell line as previously described. 458
Briefly, 70% confluent 293GP 20cm plates were co-transfected with 20ug MSGV vector plasmid 459 and 10ug RD114 envelope plasmid DNA using Lipofectamine 2000. Media was replaced at 24 460 and 48 hours post transfection. The 48HR and 72HR viral supernatants were harvested, 461 centrifuged to remove cell debris, and frozen at -80C for future use. Third generation, self-462
inactivating lentiviral supernatant was produced in the 293T packaging cell line as previously 463
described Cryopreserved T cells were thawed and activated same day with Human T-Expander CD3/CD28 477 Dynabeads (Gibco) at 3:1 beads:cell ratio in T cell media (AIMV supplemented with 5% FBS, 478
10mM HEPES, 2mM GlutaMAX, 100 U/mL penicillin, and 100ug/mL streptomycin (Gibco)). 479
Recombinant human IL-2 (Peprotech) was provided at 100 U/mL. T cells were transduced with 480 retroviral vector on days 2 and 3 post activation and maintained at 0.5-1 x10 6 cells per mL in T 481 cell media with IL-2. Unless otherwise indicated, CAR T cells were used for in vitro assays or 482 transferred into mice on day 10-11 post activation. 483
Retroviral transduction 484
Non-tissue culture treated 12-well plates were coated overnight at 4C with 1mL Retronectin 485 (Takara) at 25ug/mL in PBS. Plates were washed with PBS and blocked with 2% BSA for 15min. 486
Thawed retroviral supernatant was added at ~1mL per well and centrifuged for 2 hours at 32C 487 at 3200 RPM before the addition of cells. 488
Cell Lines 489
The Kelly neuroblastoma, EW8 Ewing's sarcoma, 143b and TC32 osteosarcoma cell lines were 490 originally obtained from ATCC. In some cases, cell lines were stably transduced with GFP and 491 firefly luciferase (GL). The CD19 + CD22 + Nalm6-GL B-ALL cell line was provided by David Barrett. 492
Nalm6-GD2 was created by co-transducing Nalm6-GL with cDNAs for GD2 synthase and GD3 493 synthase. A single cell clone was then chosen for high GD2 expression. Nalm6-22 KO and 22 low 494 have been previously described and were kindly provided by Terry Fry. All cell lines were 495 cultured in complete media (RPMI supplemented with 10% FBS, 10mM HEPES, 2mM GlutaMAX, 496 100 U/mL penicillin, and 100ug/mL streptomycin (Gibco)). 497
Flow Cytometry 498
The anti-CD19 CAR idiotype antibody was kindly provided by Bipulendu Jena and Laurence 499
Cooper 47 . The 1A7 anti-14G2a idiotype antibody was obtained from NCI-Frederick. CD22 and 500
Her2 CARs were detected using human CD22-Fc and Her2-Fc recombinant proteins (R&D). The 501 idiotype antibodies and Fc-fusion proteins were conjugated in house with Dylight488 and/or 502 650 antibody labeling kits (Thermo Fisher). T cell surface phenotype was assessed using the 503 following antibodies: 504
From BioLegend: CD4-APC-Cy7 (clone OKT4), CD8-PerCp-Cy5.5 (clone SK1), TIM3-BV510 (clone 505 F38-2E2), CD39-FITC or APC-Cy7 (clone A1), CD95-PE (clone DX2), CD3-PacBlue (clone HIT3a), 506
From eBioscience: PD1-PE-Cy7 (clone eBio J105), LAG3-PE (clone 3DS223H), CD45RO-PE-Cy7 507 (clone UCHL1), CD45-PerCp-Cy5.5 (clone HI30), 508
From BD: CD45RA-FITC or BV711 (clone HI100), CCR7-BV421 (clone 150503), CD122-BV510 509
(clone Mik-b3), CD62L-BV605 (clone DREG-56), CD4-BUV395 (clone SK3), CD8-BUV805 (clone 510 SK1 Immunocompromised NOD/SCID/IL2Rg -/-(NSG) mice were purchased from JAX and bred in-542
house. All mice were bred, housed, and treated under Stanford University IACUC (APLAC) 543 approved protocols. 6-8 week old mice were inoculated with either 1x10 6 Nalm6-GL leukemia 544 via intravenous (IV) or 0.5-1x10 6 143B osteosarcoma via intramuscular (IM) injections. All CAR T 545 cells were injected IV. Time and treatment dose are indicated in the Figure legends. Leukemia 546 progression was measured by bioluminescent imaging using the IVIS imaging system. Values 547 were analyzed using Living Image software. Solid tumor progression was followed using caliper 548 measurements of the injected leg area. 5 mice per group were treated in each experiment, and 549 each experiment was repeated 2 or 3 times as indicated. Mice were randomized to ensure 550 equal pre-treatment tumor burden before CAR T cell treatment. 551
Blood and tissue analysis 552
Peripheral blood sampling was conducted via retro-orbital blood collection under isoflurane 553 anesthesia at the indicated time points. 50µL blood was labeled with CD45, CD3, CD4, and CD8, 554 lysed using BD FACS Lysing Solution and quantified using CountBright Absolute Counting beads 555 (Thermo Fisher) on a BD Fortessa flow cytometer. 556
ATAC-seq 557 ATAC-seq library preparation was carried out as described previously 48 . Briefly, 100,000 cells 558 from each sample were sorted by FACS into CM, centrifuged at 500g at 4°C, then resuspended 559 in ATAC-seq Resuspension Buffer (RSB) (10 mM Tris-HCl, 10 mM NaCl, 3mM MgCl2) 560
supplemented with 0.1% NP-40,0.1% Tween-20, and 0.01% Digitonin. Samples were split into 561 two replicates each prior to all subsequent steps. Samples were incubated on ice for 3 minutes, 562 then washed out with 1 mL RSB supplemented with 0.1% Tween-20. Nuclei were pelleted at 563 500g for 10 minutes at 4°C. The nuclei pellet was resuspended in 50 μL transposition mix (25 μl  564 2x TD buffer, 2.5 μl transposase (Illumina), 16.5 μl PBS, 0.5 μl 1% digitonin, 0.5 μl 10% Tween-565 20, 5 μl H2O) and incubated at 37°C for 30 minutes in a thermomixer with 1000 RPM shaking. 566
The reaction was cleaned up using the Qiagen MinElute PCR Purification Kit. Libraries were PCR-567 amplified using the NEBNext Hi-Fidelity PCR Master Mix and custom primers (IDT) as described 568 previously 20 . Libraries were sufficiently amplified following 5 cycles of PCR, as indicated by qPCR 569 fluorescence curves 20 . Libraries were purified with the Qiagen MinElute PCR Purification Kit 570 and quantified with the KAPA Library Quantification Kit. Libraries were sequenced on the 571
Illumina NextSeq at the Stanford Functional Genomics Facility with paired-end 75bp reads. 572
Adapter sequences were trimmed using SeqPurge and aligned to hg19 genome using bowtie2. 573
These reads were then filtered for mitochondrial reads, low mapping quality (Q >=20), and PCR 574 duplicates using Picard tools. Then we converted the bam to a bed and got the Tn5 corrected 575 insertion sites ("+" stranded + 4 bp, "-" stranded -5 bp). To Identify peaks, we called peaks for 576 each sample using MACS2 "--shift -75 --extsize 150 --nomodel --call-summits --nolambda --577
keep-dup all -p 0.00001" using the insertion beds. To get a union peak set, we (1) extended all 578 summits to 500bp, (2) merged all summit bed files and then (3) used bedtools cluster and 579 selected the summit with the highest MACS2 score. This was then filtered by the ENCODE hg19 580 blacklist (https://www.encodeproject.org/annotations/ENCSR636HFF/), to remove peaks that 581 extend beyond the ends of chromosomes. We then annotated these peaks using HOMER and 582 computed the occurrence of a TF motif using motifmatchr in R with chromVARMotifs HOMER 583 set. To create sequencing tracks, we read the Tn5 corrected insertion sites into R and created a 584 coverage pileup binned every 100bp using rtracklayer. We then counted all insertions that fell 585 within each peak to get a counts matrix (peak x samples). To determined differential peaks we 586 first used peaks that were annotated as "TSS" as control genes or "Housekeeping Peaks" for 587
DESeq2 and then computed differential peaks with this normalization. All clustering was 588 performed using the regularized log transform values from DESeq2. Transcription factor motif 589 deviation analysis was carried out using chromVAR as described previously 21 . TF motif 590 enrichment were calculated using a hypergeometric test in R testing the representation of a 591 motif (from motifmatchr above) in a subset of peaks vs all peaks. 592
Subset RNA-seq 593
For T cell subset-specific RNA-seq, T cells were isolated from healthy donor buffy coats as 594 described above. Before activation, naïve and central memory CD4+ or CD8+ subsets were 595 isolated using a BD FACSAria cell sorter (Stem Cell FACS Core, Stanford University School of 596
Medicine) using the following markers: Naïve (CD45RA+CD45RO-, CD62L+, CCR7+, CD95-, and 597 CD122-), Central Memory (CD45RA-CD45RO+, CD62L+, CCR7+). Sorted starting populations 598
were activated, transduced, and cultured as described above. On days 7, 10, and 14 of culture, 599 CAR+ CD4+ and CD8+ cells were sorted, and RNA was isolated using Qiagen mRNEasy kit. 600
Samples were library prepped and sequenced via Illumina NextSeq paired end platform by the 601
Stanford Functional Genomics Core. 602
Bulk RNA-seq 603
For bulk RNA isolation, healthy donor T cells were prepared as described. On day 10 or 11 of 604 culture, total mRNA was isolated from 2 x 10 6 bulk CAR T cells using Qiagen RNEasy Plus mini 605 isolation kit. Bulk RNA-seq was performed by BGI America (Cambridge, MA) using the BGISEQ-606 500 platform, single end 50bp-read length, at 30 x 10 6 reads per sample. Principal component 607 analysis was performed using stats package and plots with ggplot2 package in R (version 3.5) 49 . 608
Gene set enrichment analysis was performed using the GSEA software (Broad Institute) as 609 described 50,51 . 610
Single Cell RNA-seq 611
To compare gene expression in single CD19-CAR and GD2-CAR T cells, we sorted naïve T-cell 612 subset on day 0 for subsequent single-cell analysis on day 10 using the Chromium platform (10x 613
Genomics) and the Chromium Single Cell 3' v2 Reagent Kit according to the manufacturer's 614 instructions. cDNA libraries were prepared separately for CD19-CAR and GD2-CAR cells, and the 615 CD4+ cells and CD8+ cells were combined in each run to be separated bioinformatically 616 downstream. Sequencing was performed on the Illumina NextSeq system (paired-end, 26 bp 617 into read 1 and 98 bp into read 2) to a depth >100,000 reads per cell. Single-cell RNA-618 sequencing reads were aligned to the Genome Reference Consortium Human Build 38 619 (GRCh38), normalized for batch effects, and filtered for cell events using the Cell Ranger 620 software (10X Genomics). A total of 804 CD19-CAR and 726 GD2-CAR T cells were sequenced to 621 an average of 350,587 post-normalization reads per cell. The cell-gene matrix was further 622 processed using the Cell Ranger R Kit software (10X Genomics) as described 52 . Briefly, we first 623 selected genes with ≥1 unique molecular identifier (UMI) counts in any given cell. UMI counts 624
were then normalized to UMI sums for each cell and multiplied by a median UMI count across 625 cells. Next, the data were transformed by taking a natural logarithm of the resulting data 626 matrix. 627
Statistical Analysis 628
Unless otherwise noted, statistical analyses for significant differences between groups were 629 conducted using upaired 2-tailed t-tests without assuming consistent SD using GraphPad Prism 630 7. For bulk RNA-seq in Figure 2C , the nonparametric Wilcoxon matched-pair signed rank test 631 was used. Survival curves were compared using the Log-rank Mantel-Cox test. A table with the 632 full statistical analysis, including exact p values, t ratio, and dof can be found in the 633 supplementary materials. 634
Data Availability 635
The sequencing datasets generated during the current study will be made publicly available 636 upon acceptance and prior to final publication. 637 638
